Effect of Tandospirone on Mismatch Negativity and Cognitive Performance in Schizophrenia

Higuchi, Yuko; Sumiyoshi, Tomiki; Kawasaki, Yasuhiro; Ito, Toru; T, Seo; Suzuki, Michio

doi:10.1097/jcp.0b013e3181faa57d

Cited by 17 publications

(14 citation statements)

References 22 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further study with 26 schizophrenia patients treated with neuroleptics showed the efficacy of adjunctive tandospirone (30 mg/day) with regard to executive functions and verbal memory [35]. These positive effects were also documented by a more recent case report [36].…”

Section: Tandospironementioning

confidence: 93%

May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?

Buoli

Altamura

2015

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

Section: Tandospironementioning

confidence: 93%

May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?

Buoli

Altamura

2015

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Electroencephalograms (EEGs) were recorded based on the previous report from our laboratory (Sumiyoshi et al, 2006, 2009; Kawasaki et al, 2007a; Higuchi et al, 2008, 2010, 2013a,b; Itoh et al, 2011). …”

Section: Methodsmentioning

confidence: 99%

“…Measurements of dMMN/P3a/RON complex were based on our previous report (Higuchi et al, 2010). One-thousand auditory stimuli were delivered binaurally through headphones with inter-stimulus intervals 500 ms. Standard/target tones of 50/100 ms duration were randomly presented with the presentation probability of 0.9/0.1.…”

Section: Methodsmentioning

confidence: 99%

Mismatch Negativity and P3a/Reorienting Complex in Subjects with Schizophrenia or At-Risk Mental State

Higuchi

Miyanishi

et al. 2014

Front. Behav. Neurosci.

Self Cite

View full text Add to dashboard Cite

Introduction: We measured duration mismatch negativity (dMMN), P3a, and reorienting negativity (RON) in subjects with at-risk mental state (ARMS), patients with first-episode or chronic schizophrenia, and healthy volunteers. The main interest was to determine if these event-related potentials provide a biomarker associated with progression to overt schizophrenia in ARMS subjects.Methods: Nineteen ARMS subjects meeting the criteria of the Comprehensive Assessment of ARMS, 38 patients with schizophrenia (19 first-episode and 19 chronic), and 19 healthy controls participated in the study. dMMN, P3a, and RON were measured with an auditory odd-ball paradigm at baseline.Results: During the follow-up period (2.2 years), 4 out of the 19 ARMS subjects transitioned to schizophrenia (Converters) while 15 did not (non-Converters). dMMN amplitudes of Converters were significantly smaller than those of non-Converters at frontal and central electrodes before onset of illness. dMMN amplitudes of non-Converters did not differ from those of healthy controls, while Converters showed significantly smaller dMMN amplitudes compared to control subjects. RON amplitudes were also reduced at frontal and central electrodes in subjects with schizophrenia, but not ARMS. Converter subjects tended to show smaller RON amplitudes compared to non-Converters.Conclusions: Our data confirm that diminished dMMN amplitudes provide a biomarker, which is present before and after the development of psychosis. In this respect, RON amplitudes may also be useful, as suggested for the first time based on longitudinal observations.

show abstract

“…This may explain the ability of AAPDs to augment DA release in the PFC (Sumiyoshi and Higuchi, 2013), a putative mechanism for the ability of AAPDs to enhance cognition, in a 5-HT 1A receptor-dependent manner (Diaz-Mataix et al, 2005; Bortolozzi et al, 2010). These neural events may explain the ability of augmentation therapy with tandospirone to restore mismatch negativity amplitudes (Higuchi et al, 2010), an electrophysiological measure of glutamatergic activity that is diminished in schizophrenia (Javitt et al, 2008). Other possible mechanisms may involve GABA B receptor-mediated transmissions (Gronier, 2008) or other neurotransmitters (e.g., acetylcholine).…”

Section: Neural Network Mediating Cognitive Enhancement Of Aapdsmentioning

confidence: 99%

“…For example, administration of clozapine, a 5-HT 1A agonist, increases extracellular DA concentrations in the prefrontal cortex in mice, but it does not occur in mutant mice lacking 5-HT 1A receptors (Bortolozzi et al, 2010). These neural events may explain the ability of augmentation therapy with tandospirone to restore mismatch negativity amplitudes (Higuchi et al, 2010), an electrophysiological measure of glutamatergic activity that is diminished in schizophrenia. VTA, ventral tegmental area.…”

Section: Neural Network Mediating Cognitive Enhancement Of Aapdsmentioning

confidence: 99%

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia

Sumiyoshi¹,

Higuchi²,

Uehara³

2013

Front. Behav. Neurosci.

Self Cite

View full text Add to dashboard Cite

Cognitive impairments are considered to largely affect functional outcome in patients with schizophrenia, other psychotic illnesses, or mood disorders. Specifically, there is much attention to the role of psychotropic compounds acting on serotonin (5-HT) receptors in ameliorating cognitive deficits of schizophrenia. It is noteworthy that atypical antipsychotic drugs (AAPDs), e.g., clozapine, melperone, risperidone, olanzapine, quetiapine, aripiprazole, perospirone, blonanserin, and lurasidone, have variable affinities for these receptors. Among the 5-HT receptor subtypes, the 5-HT1A receptor is attracting particular interests as a potential target for enhancing cognition, based on preclinical and clinical evidence. The neural network underlying the ability of 5-HT1A agonists to treat cognitive impairments of schizophrenia likely includes dopamine, glutamate, and gamma-aminobutyric acid neurons. A novel strategy for cognitive enhancement in psychosis may be benefited by focusing on energy metabolism in the brain. In this context, lactate plays a major role, and has been shown to protect neurons against oxidative and other stressors. In particular, our data indicate chronic treatment with tandospirone, a partial 5-HT1A agonist, recover stress-induced lactate production in the prefrontal cortex of a rat model of schizophrenia. Recent advances of electrophysiological measures, e.g., event-related potentials, and their imaging have provided insights into facilitative effects on cognition of some AAPDs acting directly or indirectly on 5-HT1A receptors. These findings are expected to promote the development of novel therapeutics for the improvement of functional outcome in people with schizophrenia.

show abstract

Effect of Tandospirone on Mismatch Negativity and Cognitive Performance in Schizophrenia

Cited by 17 publications

References 22 publications

May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?

May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?

Mismatch Negativity and P3a/Reorienting Complex in Subjects with Schizophrenia or At-Risk Mental State

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia

Contact Info

Product

Resources

About